Garvey et al. 2022 — STEP 5: Sustained Weight Loss

Semaglutide 2.4mg maintained sustained 15.2% weight loss over 104 weeks in adults with obesity, confirming long-term efficacy and safety profile.

Abstract

104-week trial demonstrating sustained 15.2% weight loss with continued semaglutide treatment.

Key Findings

Sustained weight loss of 15.2% was maintained over 104 weeks with semaglutide 2.4 mg. The study confirmed long-term efficacy and safety profile. Mean weight reduction from baseline was 15.2 kg.

Study Design

Randomized controlled trial (STEP 5)